Aptevo Therapeutics Inc.
APVO | NASDAQ
$1.84
$0 (0.00%)
At close: Sep 21, 2026, 3:59 PM ET
$1.81
-$0.03 (-1.63%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | 3.11M | 12.29M | 4.31M |
Cost of Revenue | 240K | 352K | n/a | n/a | n/a | 17.85M |
Gross Profit | -240K | -352K | n/a | 3.11M | 12.29M | -13.54M |
Operating Income | -26.31M | -24.6M | -28.88M | -28.64M | -21.4M | -27.49M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -25.97M | -24.13M | -18.65M | 7.01M | -29.41M | -30.92M |
Net Income | -25.97M | -24.13M | -17.41M | 8.03M | -28.46M | -17.75M |
Selling & General & Admin | 11.77M | 10.22M | 11.77M | 13.87M | 14.7M | 13.95M |
Research & Development | 14.54M | 14.38M | 17.11M | 17.88M | 18.99M | 17.85M |
Other Expenses | -240K | -352K | n/a | n/a | n/a | -17.85M |
Operating Expenses | 26.07M | 24.25M | 28.88M | 31.76M | 33.69M | 13.95M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 26.31M | 24.6M | 28.88M | 31.76M | 33.69M | 31.8M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 3.16K | 767.05 | 20.88 | 8.70 | 8 | 5.79 |
Shares Outstanding (Diluted) | 3.16K | 767.05 | 20.88 | 8.71 | 8 | 5.79 |
EPS (Basic) | -87.27 | -31.46K | -834.04K | 922.39K | -3.56M | -5.55M |
EPS (Diluted) | -87.27 | -31.46K | -834.04K | 921.92K | -3.56M | -5.55M |
EBITDA | -25.73M | -23.78M | -18.08M | 7.92M | -28.26M | -26.19M |
EBIT | -25.97M | -24.13M | -18.65M | 7.01M | -29.41M | -27.49M |
Depreciation & Amortization | 240K | 352K | 567K | 901K | 1.14M | 1.31M |
Add to Watchlist
Select watchlists to add or remove APVO